Increased regulatory T cells in acute lymphoblastic leukaemia patients

Hematology

Volumn 21, Issue 4, 2016, Pages 206-212

  Idris, Siti Zuleha ^a   Hassan, Norfarazieda ^a   Lee, Le Jie ^a   Md Noor, Sabariah ^a   Osman, Raudhawati ^b   Abdul Jalil, Marsitah ^a   Nordin, Abdul Jalil ^a   Abdullah, Maha ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Age; B cell acute lymphoblastic leukaemia; Regulatory T cells

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IPEX SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MORTALITY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 84983433380     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245332.2015.1101965     Document Type: Article

References (55)

1. K.A.Hogquist, T.A.Baldwin, S.C.Jameson. Central tolerance:learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772–82. doi:10.1038/nri1707
2. T.C.Metzger, M.S.Anderson. Control of central and peripheral tolerance by Aire. Immunol Rev. 2011;241(1):89–103. http://dx.doi.org/10.1111/j.1600-065X.2011.01008.x. doi:10.1111/j.1600-065X.2011.01008.x
3. L.S.Walker, A.K.Abbas. The enemy within:keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2(1):11–19. doi:10.1038/nri701
4. S.Sakaguchi, N.Sakaguchi, M.Asano, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.
5. D.Dieckmann, H.Plottner, S.Berchtold, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303–10. http://dx.doi.org/10.1084/jem.193.11.1303. doi:10.1084/jem.193.11.1303
6. M.E.Brunkow, E.W.Jeffery, K.A.Hjerrild, Paeper B, Clark LB, Yasayko SA, Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27(1):68–73. doi:10.1038/83784
7. R.S.Wildin, F.Ramsdell, J.Peake, Faravelli F, Casanova JL, Buist N, X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18–20. http://dx.doi.org/10.1038/83707. doi:10.1038/83707
8. S.Sakaguchi, T.Yamaguchi, T.Nomura, M.Ono. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87. doi:10.1016/j.cell.2008.05.009
9. E.Bettelli, M.Dastrange, M.Oukka. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA. 2005;102:5138–43. http://dx.doi.org/10.1073/pnas.0501675102. doi:10.1073/pnas.0501675102
10. Y.Wu, M.Borde, V.Heissmeyer, Feuerer M, Lapan AD, Stroud JC, FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126:375–87. doi:10.1016/j.cell.2006.05.042
11. W.Liu, A.L.Putnam, Z.Xu-Yu, Szot GL, Lee MR, Zhu S, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + Treg cells. J Exp Med. 2006;203(7):1701–11. http://dx.doi.org/10.1084/jem.20060772. doi:10.1084/jem.20060772
12. E.M.Shevach, A.M.Thornton. tTregs, pTregs, and iTregs:similarities and differences. Immunol Rev. 2014;259(1):88–102. doi:10.1111/imr.12160
13. D.K.Sojka, Y.H.Huang, D.J.Fowell. Mechanisms of regulatory T-cell suppression – a diverse arsenal for a moving target. Immunology. 2008;124(1):13–22. http://dx.doi.org/10.1111/j.1365-2567.2008.02813.x. doi:10.1111/j.1365-2567.2008.02813.x
14. S.Z.Josefowicz, L.F.Lu, A.Y.Rudensky. Regulatory T cells:mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64. doi:10.1146/annurev.immunol.25.022106.141623
15. L.S.Taams, D.B.Palmer, A.N.Akbar, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006;118(1):1–9. http://dx.doi.org/10.1111/j.1365-2567.2006.02348.x. doi:10.1111/j.1365-2567.2006.02348.x
16. R.Bacchetta, E.Gambineri, M.G.Roncarolo. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol. 2007;120(2):227–35. doi:10.1016/j.jaci.2007.06.023
17. D.Mougiakakos, A.Choudhury, A.Lladser, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57–117. http://dx.doi.org/10.1016/S0065-230X(10)07003-X. doi:10.1016/S0065-230X(10)07003-X
18. K.Oleinika, R.J.Nibbs, G.J.Graham, A.R.Fraser. Suppression, subversion and escape:the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171:36–45. doi:10.1111/j.1365-2249.2012.04657.x
19. K.Kono, H.Kawaida, A.Takahashi, Sugai H, Mimura K, Miyagawa N, CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064–71. http://dx.doi.org/10.1007/s00262-005-0092-8. doi:10.1007/s00262-005-0092-8
20. J.Fu, D.Xu, Z.Liu, Shi M, Zhao P, Fu B, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–39. doi:10.1053/j.gastro.2007.03.102
21. H.Jiang, C.Gebhardt, L.Umansky, Beckhove P, Schulze TJ, Utikal J, Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352–60. doi:10.1002/ijc.29297.
22. T.Hasegawa, H.Suzuki, T.Yamaura, Muto S, Okabe N, Osugi J, Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2(5):685–94.
23. A.A.Thomas, J.L.Fisher, G.J.Rahme, Hampton TH, Baron U, Olek S, Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol. 2015;17(6):801–9.
24. K.P.Lim, N.A.Chun, S.M.Ismail, Abraham M, Yusoff MN, Zain RB, CD4+ CD25hiCD127 low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One. 2014;9(8):e103975. doi:10.1371/journal.pone.0103975. eCollection 2014. http://dx.doi.org/10.1371/journal.pone.0103975.
25. E.Lukesova, J.Boucek, E.Rotnaglova, Salakova M, Koslabova E, Grega M, High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed Res Int. 2014;2014:303929. doi:10.1155/2014/303929
26. M.Idorn, T.Køllgaard, P.Kongsted, Sengeløv L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63(11):1177–87. http://dx.doi.org/10.1007/s00262-014-1591-2. doi:10.1007/s00262-014-1591-2
27. A.Ling, S.Edin, M.L.Wikberg, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–9. doi:10.1038/bjc.2014.161
28. K.Nakagawa, K.Tanaka, Y.Homma, Nojiri K, Kumamoto T, Takeda K. Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(1):180–6. http://dx.doi.org/10.1245/s10434-014-3974-1. doi:10.1245/s10434-014-3974-1
29. E.J.Sayour, P.McLendon, R.McLendon, De Leon G, Reynolds R, Kresak J, Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64(4):419–27.
30. S.Liu, W.D.Foulkes, S.Leung, Gao D, Lau S, Kos Z, Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432. doi:10.1186/s13058-014-0432-8
31. J.Wang, X.Y.Ke. The four types of Tregs in malignant lymphomas. J Hematol Oncol. 2011;4:50. http://dx.doi.org/10.1186/1756-8722-4-50. doi:10.1186/1756-8722-4-50
32. S.P.Wallis, N.D.Stafford, J.Greenman. Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. Head Neck. 2015;37(3):449–59. doi:10.1002/hed.23736
33. C.Craddock. Acute leukaemias. Medicine. 2009;37(4):190–4. http://dx.doi.org/10.1016/j.mpmed.2009.01.007. doi:10.1016/j.mpmed.2009.01.007
34. T.Haferlach, W.Kern, S.Schnittger, C.Schoch. Modern diagnostics in acute leukaemias. Crit Rev Oncol/Hematol. 2005;56:223–34. doi:10.1016/j.critrevonc.2004.04.008
35. N.H.Russell. Biology of acute leukaemia. Lancet. 1997;349:118–22. http://dx.doi.org/10.1016/S0140-6736(96)07185-1. doi:10.1016/S0140-6736(96)07185-1
36. J.F.San Miguel, M.B.Vidriales, C.Lopez-Berges, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukaemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746–51. doi:10.1182/blood.V98.6.1746
37. C.H.Piu, C.G.Mullighan, W.E.Evans, M.V.Relling. Pediatric acute lymphoblastic leukaemia:where are we going and how do we get there? Blood. 2012;120:1165–74. http://dx.doi.org/10.1182/blood-2012-05-378943. doi:10.1182/blood-2012-05-378943
38. M.A.Teitell, P.P.Pandolfi. Molecular genetics of acute lymphoblastic leukaemia. Annu Rev Pathol Mech. 2009;4:175–98.
39. J.Wiemels. Chromosomal translocations in childhood leukaemia natural history, mechanisms, and epidemiology. J Natl Cancer Inst Monogr. 2008;39:87–90. http://dx.doi.org/10.1093/jncimonographs/lgn006. doi:10.1093/jncimonographs/lgn006
40. G.Juliusson, P.Antunovic, A.Derolf, Lehmann S, Möllgård L, Stockelberg D, Age and acute myeloid leukaemia:real world data on decision to treat and outcomes from the Swedish Acute Leukaemia Registry. Blood. 2009;113(18):4179–87. doi:10.1182/blood-2008-07-172007
41. C.Ustun, J.S.Miller, D.H.Munn, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukaemia:is it time for immunomodulation? Blood. 2011;118:5084–95. http://dx.doi.org/10.1182/blood-2011-07-365817. doi:10.1182/blood-2011-07-365817
42. X.Wang, J.Zheng, J.Liu, Yao J, He Y, Li X, Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukaemia patients. Eur J Haematol. 2005;75(6):468–76. doi:10.1111/j.1600-0609.2005.00537.x
43. M.J.Szczepanski, M.Szajnik, M.Czystowska, Mandapathil M, Strauss L, Welsh A, Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukaemia. Clin Cancer Res. 2009;15:3325–32. http://dx.doi.org/10.1158/1078-0432.CCR-08-3010. doi:10.1158/1078-0432.CCR-08-3010
44. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukaemia. Int J Cancer. 2011;129:1373–81. doi:10.1002/ijc.25791
45. Q.Zhou, C.Bucher, M.E.Munger, Highfill SL, Tolar J, Munn DH, Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukaemia. Blood. 2009;114(18):3793–802. http://dx.doi.org/10.1182/blood-2009-03-208181. doi:10.1182/blood-2009-03-208181
46. O.C.Goodyear, M.Dennis, N.Y.Jilani, Loke J, Siddique S, Ryan G, Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukaemia (AML). Blood. 2012;119(14):3361–9. doi:10.1182/blood-2011-09-377044
47. C.P.Wu, X.Qing, C.Y.Wu, Zhu H, Zhou HY. Immunophenotype and increased presence of CD4(+)CD25(+) regulatory T cells in patients with acute lymphoblastic leukaemia. Oncol Lett. 2012;3:421–4.
48. K.Bhattacharya, S.Chandra, C.Mandal. Critical stoichiometric ratio of CD4(+) CD25(+) FoxP3(+) regulatory T cells and CD4(+) CD25(−) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia. Immunology. 2014;142(1):124–39. http://dx.doi.org/10.1111/imm.12237. doi:10.1111/imm.12237
49. S.Fiorentino, M.Chopin, H.Dastot, Boissel N, Reboul M, Legrès L, Disruption of T cell regulatory pathways is necessary for immunotherapeutic cure of T cell acute lymphoblastic leukaemia in mice. Eur Cytokine Netw. 2005;16(4):300–8.
50. M.Smith, D.Arthur, B.Camitta, Carroll AJ, Crist W, Gaynon P, Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukaemia. J Clin Oncol. 1996;14(1):18–24.
51. A.Möricke, M.Zimmermann, A.Reiter, Gadner H, Odenwald E, Harbott J, Prognostic impact of age in children and adolescents with acute lymphoblastic leukaemia:data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr. 2005;217(6):310–20. doi:10.1055/s-2005-872515
52. A.M.Wolf, D.Wolf, M.Steurer, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606–12.
53. S.A.Rosenberg, J.C.Yang, N.P.Restifo. Cancer immunotherapy:moving beyond current vaccines. Nat Med. 2004;10(9):909–15. http://dx.doi.org/10.1038/nm1100. doi:10.1038/nm1100
54. F.Wimmers, G.Schreibelt, A.E.Sköld, Figdor CG, De Vries IJ. Paradigm shift in dendritic cell-based immunotherapy:from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol. 2014;5:165. doi:10.3389/fimmu.2014.00165
55. A.Bonertz, J.Weitz, D.H.Pietsch, Rahbari NN, Schlude C, Ge Y, Antigen specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 2009;119:3311–21.